Pooled Analysis of Loss of Heterozygosity in Breast Cancer: A Genome Scan Provides Comparative Evidence for Multiple Tumor Suppressors and Identifies Novel Candidate Regions

American Journal of Human Genetics

Volumn 73, Issue 4, 2003, Pages 748-767

  Miller, Brian J ^a   Wang, Daolong ^c   Krahe, Ralf ^b,e   Wright, Fred A ^b,c,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; BREAST CANCER; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 19P; CHROMOSOME 21Q; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME FRAGILE SITE; CHROMOSOME LOSS; CONTROLLED STUDY; DATA BASE; GENE IDENTIFICATION; GENE LOCUS; GENETIC ANALYSIS; GENETIC STABILITY; GENOME; HETEROZYGOSITY LOSS; HUMAN; MARKER CHROMOSOME; MOLECULAR MODEL; PRIORITY JOURNAL; REPRODUCIBILITY; TUMOR SUPPRESSOR GENE;

EID: 0142059657     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/378522     Document Type: Article

References (111)

1. Adelaide J, Chaffanet M, Imbert A, Allione F, Geneix J, Popovici C, van Alewijk D, Trapman J, Zeillinger R, Borresen-Dale AL, Lidereau R, Birnbaum D, Pebusque MJ (1998) Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. Genes Chromosomes Cancer 22:186-199
2. American Cancer Society (2002) ACS breast cancer facts and figures, 2001-2002. American Cancer Society, Atlanta
3. Arlt MF, Miller DE, Beer DG, Glover TW (2002) Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 33:82-92
4. Becker KF, Kremmer E, Eulitz M, Schulz S, Mages J, Handschuh G, Wheelock MJ, Cleton-Jansen AM, Hofler H, Becker I (2002) Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies. J Pathol 197:567-574
5. Bednarek AK, Keek-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz CM (2001) WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61:8068-8073
6. Bell DW, Erban J, Sgroi DC, Haber DA (2002) Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res 62:2741-2743
7. Benachenhou N, Guiral S, Gorska-Flipot I, Labuda D, Sinnett D (1999) Frequent loss of heterozygosity at the DNA mismatch-repair loci hMLH1 and hMSH3 in sporadic breast cancer. Br J Cancer 79:1012-1017
8. Bieche I, Khodja A, Lidereau R (1998) Deletion mapping in breast tumor cell lines points to two distinct tumor-suppressor genes in the 1p32-pter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma. Oncol Rep 5:267-272
9. _ (1999) Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer 24:255-263
10. Bogliolo M, Cabre O, Callen E, Castillo V, Creus A, Marcos R, Surralles J (2002) The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis 17:529-538
11. Brown VL, Proby CM, Barnes DM, Kelsell DP (2002) Lack of mutations within ST7 gene in tumour-derived cell lines and primary epithelial tumours. Br J Cancer 87:208-211
12. Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, Godwin AK (1999) Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res 59:4973-4983
13. Buchholz TA, Weil MM, Story MD, Strom EA, Brock WA, McNeese MD (1999) Tumor suppressor genes and breast cancer. Radiat Oncol Investig 7:55-65
14. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC (2001) Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20:4169-4179
15. Callahan R (1998) Somatic mutations that contribute to breast cancer. Biochem Soc Symp 63:211-221
16. Callahan R, Cropp C, Sheng ZM, Merlo G, Steeg P, Liscia D, Lidereau R (1993) Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors. J Cell Biochem Suppl 17G:167-172
17. Callen DF, Crawford J, Derwas C, Cleton-Jansen AM, Cornelisse CJ, Baker E (2002) Defining regions of loss of heterozygosity of 16q in breast cancer cell lines. Cancer Genet Cytogenet 133:76-82
18. Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA (2000) Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA 97:12776-12781
19. Castells A, Gusella JF, Ramesh V, Rustgi AK (2000) A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836-2839
20. Chalmers IJ, Aubele M, Hartmann E, Braungart E, Werner M, Hofler H, Atkinson MJ (2001) Mapping the chromosome 16 cadherin gene cluster to a minimal deleted region in ductal breast cancer. Cancer Genet Cytogenet 126:39-44
21. Chen T, Sahin A, Aldaz CM (1996) Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56:5605-5609
22. Chen W, Butler M, Rao PH, Chaganti SR, Louie DC, Dalla-Favera R, Chaganti RS (1998) The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5′ regulatory region and chromosomal breakpoints distant from the gene. Oncogene 17:1717-1722
23. Chen Z, Ge Y, Landman N, Kang JX (2002) Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2:18
24. Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee P, Cornelisse CJ (1994) At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer 9:101-107
25. Collins A, Frezal J, Teague J, Morton NE (1996) A metric map of humans: 23,500 loci in 850 bands. Proc Natl Acad Sci USA 93:14771-14775
26. Couch FJ, Weber BL (1997) Breast cancer. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 537-564
27. Cox DR, Hinkley DV (1974) Theoretical statistics. Chapman and Hall, London
28. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
29. Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, Schaffer AA (1999) Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol 6:37-51
30. Devilee P, Cleton-Jansen AM, Cornelisse CJ (2001) Ever since Knudson. Trends Genet 17:569-573
31. Devilee P, Cornelisse CJ (1994) Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113-130
32. Devilee P, van Vliet M, Kuipers-Dijkshoorn N, Pearson PL, Cornelisse CJ (1991) Somatic genetic changes on chromosome 18 in breast carcinomas: is the DCC gene involved? Oncogene 6:311-315
33. Dong SM, Sidransky D (2002) Absence of ST7 gene alterations in human cancer. Clin Cancer Res 8:2939-2941
34. Driouch K, Dorion-Bonnet F, Briffod M, Champeme MH, Longy M, Lidereau R (1997) Loss of heterozygosity on chromosome arm 16q in breast cancer metastases. Genes Chromosomes Cancer 19:185-191
35. Ellisen LW, Haber DA (1998) Hereditary breast cancer. Annu Rev Med 49:425-436
36. Fiucci G, Ravid D, Reich R, Liscovitch M (2002) Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21: 2365-2375
37. Forsti A, Luo L, Vorechovsky I, Soderberg M, Lichtenstein P, Hemminki K (2001) Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer. Carcinogenesis 22:27-33
38. Futreal PA, Kasprzyk A, Birney E, Mullikin JC, Wooster R, Stratton MR (2001) Cancer and genomics. Nature 409:850-852
39. Gaki V, Tsopanomichalou M, Sourvinos G, Tsiftsis D, Spandidos DA (2000) Allelic loss in chromosomal region 1q21-23 in breast cancer is associated with peritumoral angiolymphatic invasion and extensive intraductal component. Eur J Surg Oncol 26:455-460
40. Geck P, Sonnenschein C, Soto AM (2001) The D13S171 marker, misannotated to BRCA2, links the AS3 gene to various cancers. Am J Hum Genet 69:461-463
41. Geck P, Szelei J, Jimenez J, Sonnenschein C, Soto AM (1999) Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: a new suppressor candidate on chromosome 13, in the BRCA2-Rb1 locus. J Steroid Biochem Mol Biol 68:41-50
42. Gentile M, Wiman A, Thorstenson S, Loman N, Borg A, Wingren S (2001) Deletion mapping of chromosome segment 11q24-25, exhibiting extensive allelic loss in early onset breast cancer. Int J Cancer 92:208-213
43. Guerardel C, Deltour S, Pinte S, Monte D, Begue A, Godwin AK, Leprince D (2001 ) Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J Biol Chem 276:3078-3089
44. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353
45. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99:13647-13652
46. Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM (1999) Reduced expression of APC and DCC gene protein in breast cancer. Histopathology 35:249-256
47. Hsu YY, Wang YH (2002) Human fragile site FRA16B DNA excludes nucleosomes in the presence of distamycin. J Biol Chem 277:17315-17319
48. Huebner K, Croce CM (2001) FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 1:214-221
49. Huiping C, Jonasson JG, Agnarsson BA, Sigbjornsdottir BI, Huebner K, Ingvarsson S (2000) Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer. Eur J Cancer 36:1552-1557
50. Kainu T, Juo SH, Desper R, Schaffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, et al (2000) Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 97:9603-9608
51. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821
52. Kerangueven F, Allione F, Noguchi T, Adelaide J, Sobol H, Jacquemier J, Birnbaum D (1995) Patterns of loss of heterozygosity at loci from chromosome arm 13q suggests a possible involvement of BRCA2 in sporadic breast tumors. Genes Chromosomes Cancer 13:291-294
53. Kerangueven F, Eisinger F, Noguchi T, Allione F, Wargniez V, Eng C, Padberg G, Theillet C, Jacquemier J, Longy M, Sobol H, Birnbaum D (1997) Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene 14:339-347
54. Kiss H, Yang Y, Kiss C, Andersson K, Klein G, Imreh S, Dumanski JP (2002) The transcriptional map of the common eliminated region 1 (C3CER1) in 3p21.3. Eur J Hum Genet 10:52-61
55. Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, Powell JA, Hinze SJ, Gardner AE, Spendlove HE, O'Callaghan NJ, Cleton-Jansen AM, Cornelisse C, Whitmore SA, Crawford J, Kremmidiotis G, Sutherland GR, Callen DF (2002) CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Res 62:4599-4604
56. Kollias J, Man S, Marafie M, Carpenter K, Pinder S, Ellis IO, Blamey RW, Cross G, Brook JD (2000) Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat 64:241-251
57. Kolodner RD, Putnam CD, Myung K (2002) Maintenance of genome stability in Saccharomyces cerevisiae. Science 297:552-557
58. Komiya A, Suzuki H, Ueda T, Aida S, Ito N, Shiraishi T, Yatani R, Emi M, Yasuda K, Shimazaki J, Ito H (1997) PRLTS gene alterations in human prostate cancer. Jpn J Cancer Res 88:389-93.
59. Kremmidiotis G, Baker E, Crawford J, Eyre HJ, Nahmias J, Callen DF (1998) Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics 49:467-471
60. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98:11563-11568
61. Lange K, Boehnke M, Cox DR, Lunetta KL (1995) Statistical methods for polyploid radiation hybrid mapping. Genome Res 5:136-150
62. Lasko D, Cavenee W, Nordenskjold M (1991) Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25:281-314
63. Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI (1998) An FHIT tumor suppressor gene? Genes Chromosomes Cancer 21:281-289
64. Liu CX, Musco S, Lisitsina NM, Yaklichkin SY, Lisitsyn NA (2000) Genomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics 69:271-274
65. Lucke CD, Philpott A, Metcalfe JC, Thompson AM, Hughes-Davies L, Kemp PR, Hesketh R (2001) Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer. Cancer Res 61:482-485
66. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R (1996) Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 35:55-65
67. Mahoney PA, Weber U, Onofrechuk P, Biessmann H, Bryant PJ, Goodman CS (1991) The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 67:853-868
68. Maitra A, Wistuba, II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF, Minna JD (2001) High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 159:119-130
69. Matsuda S, Rouault J, Magaud J, Berthet C (2001) In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497:67-72
70. Matsumoto S, Kasumi F, Sakamoto G, Onda M, Nakamura Y, Emi M (1997) Detailed deletion mapping of chromosome arm 3p in breast cancers: a 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors. Genes Chromosomes Cancer 20:268-274
71. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T (2001) Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67:61-70
72. Mitelman F (2000) Recurrent chromosome aberrations in cancer. Mutat Res 462:247-253
73. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793
74. Murphy LC, Wang M, Coutt A, Dotzlaw H (1996) Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J Clin Endocrinol Metab 81:1420-1427
75. Nagai H, Negrini M, Carter SL, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM (1995) Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 55:1752-1757
76. Nathanson KL, Wooster R, Weber BL, Nathanson KN (2001) Breast cancer genetics: what we know and what we need. Nat Med 7:552-556
77. Newsham IF, Hadjistilianou T, Cavenee WK (1997) Retinoblastoma. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 363-392
78. Newton MA, Gould MN, Reznikoff CA, Haag JD (1998) On the statistical analysis of allelic-loss data. Stat Med 17:1425-1445
79. Newton MA, Lee Y (2000) Inferring the location and effect of tumor suppressor genes by instability-selection modeling of allelic-loss data. Biometrics 56:1088-1097
80. Noviello C, Courjal F, Theillet C (1996) Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 2:1601-1606
81. Oesterreich S, Allredl DC, Mohsin SK, Zhang Q, Wong H, Lee AV, Osborne CK, O'Connell P (2001) High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer 84:493-498
82. Olopade OI, Bohlander SK, Pomykala H, Maltepe E, Van Melle E, Le Beau MM, Diaz MO (1992) Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14:437-443
83. Osborne RJ, Hamshere MG (2000) A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 60:3706-3712
84. Ott J (1999) Analysis of human genetic linkage. Johns Hopkins University Press, Baltimore
85. Ott L, Longnecker MT, Ott RL (2000) An introduction to statistical methods and data analysis. Brooks/Cole, London
86. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
87. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, Donis-Keller H (1996) Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 56:606-611
88. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99:12963-12968
89. Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G (2002) Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics 80:303-310
90. Rassool FV, Le Beau MM, Shen ML, Neilly ME, Espinosa R 3rd, Ong ST, Boldog F, Drabkin H, McCarroll R, McKeithan TW (1996) Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2. Genomics 35:109-117
91. Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I, Schwendel A (2000) Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89:305-310
92. Salicioni AM, Xi M, Vanderveer LA, Balsara B, Testa JR, Dunbrack RL Jr, Godwin AK (2000) Identification and structural analysis of human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins that interact with OVCA1, a candidate tumor suppressor. Genomics 69:54-62
93. Schuler GD (1997) Sequence mapping by electronic PCR. Genome Res 7:541-550
94. Seitz S, Poppe K, Fischer J, Nothnagel A, Estevez-Schwarz L, Haensch W, Schlag PM, Scherneck S (2001) Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194:318-326
95. Seitz S, Rohde K, Bender E, Nothnagel A, Kolble K, Schlag PM, Scherneck S (1997) Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. Oncogene 14:741-743
96. Sham P (2001) Shifting paradigms in gene-mapping methodology for complex traits. Pharmacogenomics 2:195-202
97. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW (2000) Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60:3884-3892
98. Shinagawa T, Nomura T, Colmenares C, Ohira M, Nakagawara A, Ishii S (2001) Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene 20: 8100-8108
99. Smith DI, Huang H, Wang L (1998) Common fragile sites and cancer (review). Int J Oncol 12:187-196
100. Stiewe T, Putzer BM (2002) Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 9:237-245
101. Strachan T, Read AP (1999) Human molecular genetics. Wiley-Liss, Hoboken, NJ
102. Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, et al (2002) Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci USA 99:827-831
103. Thompson SG (1998) Meta-analysis of clinical trials. In: Armitage P, Colton T (eds) Encyclopedia of biostatistics. Wiley, New York, pp 2570-2579
104. Tomlinson IP, Lambros MB, Roylance RR (2002) Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosomes Cancer 34:349-353
105. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF (2001) Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61:4556-4560
106. Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF (1999) A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res 59:35-43
107. Utada Y, Haga S, Kajiwara T, Kasumi F, Sakamoto G, Nakamura Y, Emi M (2000) Mapping of target regions of allelic loss in primary breast cancers to 1-cM intervals on genomic contigs at 6q21 and 6q25.3. Jpn J Cancer Res 91:293-300
108. White GR, Stack M, Santibanez-Koref M, Liscia DS, Venesio T, Wang JC, Helms C, Donis-Keller H, Betticher DC, Altermatt HJ, Hoban PR, Heighway J (1996) High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. Br J Cancer 74:863-870
109. Wilentz RE, Argani P, Hruban RH (2001) Loss of heterozygosity or intragenic mutation, which comes first? Am J Pathol 158:1561-1563
110. Yunis JJ, Soreng AL (1984) Constitutive fragile sites and cancer. Science 226:1199-1204
111. Zenklusen JC, Conti CJ, Green ED (2001) Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat Genet 27:392-398